Oxford’s recovery trial to evaluate REGN-COV2 for COVID-19 treatment
Category: #health  By Nikita Chaurasia  Date: 2020-09-16
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Oxford’s recovery trial to evaluate REGN-COV2 for COVID-19 treatment

According to credible sources, the University of Oxford has announced that it will be initiating the Recovery Trial for testing REGN-COV2, an experimental drug developed for the treatment of the COVID-19 virus.

Sources with relevant information stated that a batch of COVID-19 patients in most of NHS (National Health Service) acute hospitals will be randomly subjected to the testing of the novel drug.

For the record, REGN-COV2 has been developed by U.S.-based Regeneron Pharmaceuticals Inc. by combining two human antibodies that neutralize the mutant viruses. The company had previously developed a similar drug against the Ebola virus.

Unlike the initially developed dexamethasone, the new drug specifically targets the COVID-19 virus and has successfully proceeded to its last stage trials in the U.S.

Peter Horby, Chief investigator of the trial as well as a professor of emerging infectious diseases and global health at the Oxford University, was reported stating that although the university has observed positive outcomes of dexamethasone while treating COVID-19 patients, additional new drugs need to be explored to cope with the soaring death rate.

Martin Landray, a professor of medicine & epidemiology and Deputy Chief investigator of the trial expressed his enthusiasm towards the development and stated that the Recovery trial will enable vigorous assessment of REGN-COV2 among hospitalized patients.

However, experts are skeptical over the affordability of the new antibody vaccine, considering the cost of dexamethasone was around £5 to treat a patient with coronavirus.

In other news, British researchers will reportedly test inhaled COVID-19 vaccines developed by Imperial College and Oxford University. As per reliable sources, the trial is aimed at checking whether direct dosage to the respiratory tract can give a better immune response than conventional dosage methods. 

Source credits: https://www.theguardian.com/world/2020/sep/14/new-antibody-drug-added-to-oxford-university-trial-of-covid-19-treatments

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

U.K.’s competition regulator might look into the music streaming space

U.K.’s competition regulator might look into the music streaming space

By Nikita Chaurasia

The Competition and Markets Authority of the U.K. has revealed plans to launch a probe targeting the country’s music streaming market to ascertain if it is sufficiently consumer-centric and competitive. The announcement came after a U.K. parli...

India’s vaccination drive slows down as dose gap holds back output

India’s vaccination drive slows down as dose gap holds back output

By Nikita Chaurasia

India’s vaccination efforts have reportedly slowed down despite stockpiling vaccines as authorities are maintaining a more than usual gap between two shots. This is a part of the strategy to boost vaccine coverage in the country. The domestic ...

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

By Nikita Chaurasia

The McPlant patty is developed in collaboration with Beyond Meat Inc. It will be prepared using vegetarian ingredients like peas, potatoes, and rice. McDonald’s will reportedly start offering its first vegetarian option in the U.S., the ne...